Hagiwara A, Sakakura C, Shirasu M, Yamasaki J, Togawa T, Takahashi T, Muranishi S, Hyon S, Ikada Y
First Department of Surgery, Kyoto Prefectural University of Medicine, Japan.
Anticancer Drugs. 1998 Mar;9(3):287-9. doi: 10.1097/00001813-199803000-00012.
The delivery formulation 5-FU-MS [5-fluorouracil (5-FU) incorporated in microspheres composed of a poly(glycolide-co-lactide) matrix] slowly releases 5-FU over 3 weeks. 5-FU-MS delivers higher concentrations of the drug to the i.p. tissues for a longer period of time with lower blood plasma concentrations than does an aqueous 5-FU solution and reduces toxicity. In this study, we evaluated the therapeutic effects of 5-FU-MS on peritoneal carcinomatosis in mice. Four days after an i.p. inoculation with Colon 26 or B-16 PC melanoma, 5-FU at 200 mg/kg was administered i.p. as 5-FU-MS or as an aqueous solution of 5-FU. 5-FU-MS extended the survival of mice bearing Colon 26 or B-16 PC melanoma significantly better than the equivalent dose of aqueous 5-FU solution.
递送制剂5-氟尿嘧啶微球（5-FU-MS，即5-氟尿嘧啶掺入由聚（乙交酯-共-丙交酯）基质组成的微球中）在3周内缓慢释放5-氟尿嘧啶。与5-氟尿嘧啶水溶液相比，5-FU-MS能在更长时间内将更高浓度的药物递送至腹腔组织，同时血浆浓度更低，并降低了毒性。在本研究中，我们评估了5-FU-MS对小鼠腹膜癌的治疗效果。腹腔接种结肠26或B-16 PC黑色素瘤4天后，以5-FU-MS或5-氟尿嘧啶水溶液的形式腹腔注射200 mg/kg的5-氟尿嘧啶。5-FU-MS显著延长了荷结肠26或B-16 PC黑色素瘤小鼠的生存期，效果明显优于同等剂量的5-氟尿嘧啶水溶液。
